Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age \> 18 years~* Diagnosis of diabetes mellitus (type 1 or 2)Any one of the following will be considered to be sufficient evidence that diabetes is present:Current regular use of insulin for treatment of diabetes or current regular use of oral anti-hyperglycemia agent for the treatment of diabetes~* Clinical evidence of retinal thickening due to macular edema involving the center of the macula, associated with diabetic retinopathy.~* Previous history of two consecutive intravitreal bevacizumab injections for the treatment of diabetic macular edema with documented incomplete resolution of central subfield thickening by OCT (consecutive injections administered \< 7 weeks apart and within the past 12 months).~* Central diabetic macular edema present on clinical examination and OCT testing with central 1mm subfield thickness greater than 300 microns as measured on SD-OCT.~* Visual acuity score greater than or equal to 19 letters (20/400) and less than or equal to 73 letters (20/40) by the ETDRS visual acuity protocol.~* Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography~Exclusion Criteria:~* Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.~* Participation in another ocular investigation or trial simultaneously~* Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110)~* Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism, drug abuse)~* Evidence of vitreoretinal interface abnormality after ocular exam or OCT that may be contributing to the macular edema~* An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or geographic atrophy)~* Presence of another ocular condition that may affect the visual acuity or macular edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)~* Evidence of neovascularization of the iris or retina~* Evidence of central atrophy or fibrosis in the study eye~* Presence of substantial cataract, one that might decrease the vision by 3 or more lines of vision at sometime during the study.~* History of vitreous surgery in the study eye~* History of cataract surgery within 6 months of enrollment.~* History of YAG capsulotomy within 2 months of enrollment.~* Visual acuity \<20/400 in the fellow eye~* Uncontrolled glaucoma (pressure \>30) despite treatment with glaucoma medications.~* History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5mg and 2.0mgRanibizumab (Type: EXPERIMENTAL): Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.

Based on this trial design, predict the completion outcome and termination type (if applicable).